Home > Report Information

Analyzing the Global Diabetes Market

Aruvian's R'search
February 1, 2012
205 Pages - SKU: ARVN6801012

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.

Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.

Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Currently, the US remains the single largest source of product revenues in diabetes management, at roughly 37% of the global market, but that percentage is expected to drop to 28% by 2018, primarily as a result of significant growth in the Asia-Pacific region.

Significant R&D has been observed in the pre-insulin market leading to the development of several novel and safer therapies. The comparative performance of these therapies, such as the DPP-IV inhibitors and GLP-1 analogs is expected to shape the diabetes market landscape through 2015 and in the long term.

Aruvians Rsearch analyzes the Global Diabetes Market in its research offering Analyzing the Global Diabetes Market. The report is a comprehensive analysis of the global diabetes industry.

The report begins with an introduction to diabetes. We analyze the basics of diabetes such as the different types of diabetes including Type 1 diabetes, Type 2 diabetes, gestational diabetes, and others. Complications with diabetes, how the disease is diagnosed, how the extent of diabetes is estimated, diabetes pathophysiology, and the treatment for diabetes are analyzed in this section. We also look at diabetes epidemiology.

Moving to the next section, we analyze the global diabetes market through a market overview and an analysis of the market by diabetes drug classes. We take the drug classes to be insulin, insulin secretagogues, insulin sensitizers, and incretin mimetics. We also analyze the industry through an industry segmentation and an analysis of the leading industry products such as Lantus, Actos, Januvia, Novorapid, and others. We look at the sales figures of the leading 20 products in the industry.

An analysis of the global diabetes industry is not complete without an analysis of the market for insulin. We analyze the market for insulin through an industry overview, and an analysis of the market for human insulin. Within the market for human insulin we analyze the following market segments: fast-acting human insulin analogs, intermediate-acting human insulin analogs, long-acting human insulin analogs, and intermediate and fast-acting human insulin analogs.

With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of diabetes. Some of these novel emerging drug classes for diabetes treatment are analyzed in our report. We analyze alpha-glucosidase inhibitors such as Basen, biguanides such as glucophages, DPP-IV inhibitors such as Januvia, glitazones such as Actos, GLP-1 agonists such as Victoza and Byetta, sulfonylureas such as Amaryl, amongst others.

Moving on, we carry out an analysis of some of the key molecules used in the treatment of diabetes today. Some of the molecules analyzed include Degludec, Victoza, Syncria, amongst others.

An analysis of the diabetes market in India and China, two of the countries with the largest prevalence of diabetes, is also included, along with a look at industry research and development.

Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global diabetes industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, a financial analysis, and an analysis of their presence in the diabetes market. We also look at their diabetes R&D pipeline, along with the company strategy for future growth in the diabetes industry. A SWOT analysis of the players completes the analysis of the major industry contributors.

Future perspective of the global diabetes market completes this in-depth profile of the global diabetes market from Aruvians Rsearch.

A. Executive Summary
B. Introduction to Diabetes: B.1 What is Diabetes?; B.2 Type 1 Diabetes; B.3 Type 2 Diabetes; B.4 Gestational Diabetes; B.5 Other Types of Diabetes (Pre-diabetes); B.6 Complications with Diabetes; B.7 Diagnosing Diabetes; B.8 Estimating the Extent of Diabetes; B.9 Diabetes Pathophysiology; B.10 Treatment for Diabetes; B.11 Diabetes Epidemiology
C. Global Diabetes Market: C.1 Market Overview; C.2 Market Analysis by Diabetes Drug Classes; C.3 Industry Segmentation; C.4 Leading Industry Products
D. Market for Insulin: D.1 Market Overview; D.2 Market for Human Insulin
E. Analysis of Novel Emerging Drug Classes for Diabetes Treatment: E.1 Alpha-glucosidase Inhibitors; E.2 Biguanides; E.3 DPP-IV Inhibitors; E.4 Glitazones; E.5 GLP-1 Agonists; E.6 Sulfonylureas; E.7 DPP-IV versus GLP-1
F. Analysis of Key Molecules: F.1 Bydureon; F.2 Dapagliflozin; F.3 Degludec; F.4 Glucokinase Activators; F.5 Lixisenatide; F.6 Syncria; F.7 Tradjenta; F.8 Victoza
G. Industry Research & Development: G.1 Research on Insulin Therapy Areas; G.2 Clinical Evidence on the Role of Certain Elements in the Body; G.3 Addressing Cardiovascular Risk Factors in Diabetes Treatment; G.4 US FDA Cardiovascular Risk Evaluation Guidelines
H. Diabetes Market in India: H.1 Market Overview; H.2 Challenges Facing the Industry
I. Diabetes Market in China: I.1 Market Overview; I.2 Challenges Facing the Industry
J. Competition in the Industry
K. Leading Industry Contributors: K.1 Eli Lilly & Co.; K.2 Merck & Co.; K.3 Novo Nordisk; K.4 Sanofi SA; K.5 Takeda Pharmaceutical Company
L. Global Diabetes Market: Future Perspective: L.1 Forecast for Top Anti-diabetic Products; L.2 Forecast for Top Anti-diabetic Molecules
M. Glossary of Terms
Figures: Figure 1: Production of Insulin; Figure 2: Algorithm for Treatment of Diabetes; Figure 3: Market Share of Diabetes by Country (%), 2010; Figure 4: Various Diabetes Drug Classes and their Market Position in 2010; Figure 5: How GLP-1 Agonists Work; Figure 6: How Degludec Works; Figure 7: How GK Activators in Type 2 Diabetes Work; Figure 8: Prevalence of Diabetes in India in 2010; Figure 9: Diabetes Products of Eli Lilly by Drug Class in 2010; Figure 10: Diabetes Products of Novo Nordisk by Drug Class in 2010; Figure 11: Diabetes Products of Sanofi SA by Drug Class in 2010; Figure 12: Diabetes Products of Takeda Pharmaceutical by Drug Class in 2010
Tables: Table 1: Prevalence of Diabetes by Region (2010-2030); Table 2: Diabetes Prevalence in Leading 20 Countries, 2010; Table 3: Sales of Anti-diabetic Drugs by Class (USD Million), 2010; Table 4: Diabetes Market Segmentation by Drug Class (USD Million) 2010-2016; Table 5: Leading 10 Diabetes Products (Sales & Market Share) (USD Million) 2010; Table 6: More Leading Diabetes Products (Sales & Market Share) (USD Million) 2010; Table 7: Different Types of Insulin Available & their Characteristics; Table 8: Sales of Human Insulin by Segments (USD Million), 2010; Table 9: Market Leaders in Fast-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2010; Table 10: Characteristics of Humalog by Eli Lilly; Table 11: Characteristics of NovoRapid by Novo Nordisk; Table 12: Table 9: Market Leaders in Intermediate-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2010; Table 13: Market Leaders in Long-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2010; Table 14: Characteristics of Lantus by Sanofi; Table 15: Market Leaders in Intermediate & Fast-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2010; Table 16: Characteristics of NovoMix by Novo Nordisk; Table 17: Major Products & their Sales in the Alpha Glucosidase Inhibitors Drug Class (USD Million) in 2010; Table 18: Major Products & their Sales in the Biguanides Drug Class (USD Million) in 2010; Table 19: Major Products & their Sales in the DPP-IV Drug Class (USD Million) in 2010; Table 20: Factors Impacting the Market for Januvia; Table 21: Major Products & their Sales in the Glitazone Drug Class (USD Million) in 2010; Table 22: Major Products & their Sales in the GLP-1 Analogue Drug Class (USD Million) in 2010; Table 23: Major Products & their Sales in the Sulfonylureas Drug Class (USD Million) in 2010; Table 24: Comparison of GLP-1 Agonists and DPP-IV Inhibitors; Table 25: Phase III Clinical Trials Results of Dapagliflozin; Table 26: Sales of Market Leaders in 2010; Table 27: Anti-diabetic Products of Eli Lilly in 2010 (Sales & Market Share); Table 28: Anti-diabetic Products of Merck & Co. in 2010 (Sales & Market Share); Table 29: Anti-diabetic Products of Novo Nordisk in 2010 (Sales & Market Share); Table 30: Anti-diabetic Products of Sanofi SA in 2010 (Sales & Market Share); Table 31: Anti-diabetic Products of Takeda Pharmaceutical in 2010 (Sales & Market Share); Table 32: Leading Anti-Diabetic Products Sales Forecast (USD Million); Table 33: Leading Anti-Diabetic Molecules Sales Forecast (USD Million)

More Global Prescription Drugs Reports

Global Pharmaceuticals & Medicine Manufacturing by IBISWorld
Global Pharmaceuticals & Medicine Manufacturing This industry comprises companies that manufacture biological, medicinal and pharmaceutical products in various forms including ampoules, tablets, capsules, vials, ointments, powders, ...

Ophthalmic Drugs: World Market Prospects 2012-2022 by Visiongain
How to find trends and revenue predictions for the ophthalmic drug industry What are the commercial prospects for treating eye disorders? Visiongain's report shows you ...

Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry by iCD Research
Synopsis This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...

Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry by iCD Research
Synopsis This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and ...

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...

See all reports like this >>

Analyzing the Global Diabetes Market

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service